Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Tumor, Subjects”

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07241767
What this trial is testing

A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer

Who this might be right for
Lung Cancer
Jiangsu HengRui Medicine Co., Ltd. 200
Testing effectiveness (Phase 2)Ended earlyNCT00989092
What this trial is testing

Darbepoetin Alfa and Anemia of Cancer

Who this might be right for
AnemiaAnemia of CancerCancer+3 more
Amgen 287
Early research (Phase 1)Study completedNCT04617314
What this trial is testing

RC108-ADC in Subjects With Advanced Malignant Solid Tumors

Who this might be right for
Solid Tumor
RemeGen Co., Ltd. 67
Testing effectiveness (Phase 2)Active Not RecruitingNCT03989414
What this trial is testing

Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Who this might be right for
Multiple Myeloma
Celgene 424
Testing effectiveness (Phase 2)Study completedNCT01506609
What this trial is testing

Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
AbbVie 294
Testing effectiveness (Phase 2)UnknownNCT04674514
What this trial is testing

APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Ascentage Pharma Group Inc. 48
Early research (Phase 1)Study completedNCT00075933
What this trial is testing

ARQ 501 in Subjects With Cancer

Who this might be right for
Cancer
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 80
Early research (Phase 1)Study completedNCT00878449
What this trial is testing

A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer

Who this might be right for
Solid Tumors
AbbVie (prior sponsor, Abbott) 12
Testing effectiveness (Phase 2)Study completedNCT02247349
What this trial is testing

BMS-986012 in Relapsed/Refractory SCLC

Who this might be right for
Small Cell Lung Cancer
Bristol-Myers Squibb 106
Large-scale testing (Phase 3)Study completedNCT01938001
What this trial is testing

Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)

Who this might be right for
Lymphoma, Non-Hodgkin
Celgene 358
Not applicableLooking for participantsNCT05762731
What this trial is testing

Screening for Lung Cancer in Subjects With Family History of Lung Cancer

Who this might be right for
Lung Cancer
The University of Hong Kong 1,520
Early research (Phase 1)Study completedNCT01725100
What this trial is testing

Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies

Who this might be right for
Cancer
GlaxoSmithKline 80
Testing effectiveness (Phase 2)Study completedNCT03611556
What this trial is testing

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

Who this might be right for
CarcinomaMetastatic Pancreatic Adenocarcinoma
MedImmune LLC 213
Large-scale testing (Phase 3)Study completedNCT02668653
What this trial is testing

Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid LeukemiaLeukemia
Daiichi Sankyo 539
Early research (Phase 1)Study completedNCT02852837
What this trial is testing

Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 50
Not applicableStudy completedNCT01524445
What this trial is testing

Retrospective Survey of Re-treatment With Bortezomib

Who this might be right for
Hematological CancerMultiple Myeloma
Janssen Pharmaceutica N.V., Belgium 35
Testing effectiveness (Phase 2)WithdrawnNCT00967512
What this trial is testing

Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course

Who this might be right for
Acute Myelogenous Leukemia
Eleos, Inc.
Early research (Phase 1)Temporarily pausedNCT06388902
What this trial is testing

A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies

Who this might be right for
Advanced Solid Malignancies
BioRay Pharmaceutical Co., Ltd. 120
Testing effectiveness (Phase 2)Looking for participantsNCT06193902
What this trial is testing

LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.

Who this might be right for
Tumor, Solid
Leucid Bio 17
Testing effectiveness (Phase 2)Study completedNCT04995419
What this trial is testing

Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy

Who this might be right for
Metastatic Urothelial Cancer
Astellas Pharma China, Inc. 40
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation